The authors further observed that treatment of cells with NRF2 agonists induced a strong antiviral response that limited SARS-CoV-2 replication, pointing to the potential role of Nrf2 in the management of COVID-19 (Olagnier et al., 2020). Here, NFE2L2 is linked to COVID-19.